Raymond James & Associates Decreases Stock Holdings in Atrion Co. (NASDAQ:ATRI)

Raymond James & Associates reduced its stake in shares of Atrion Co. (NASDAQ:ATRI – Get Rating) by 8.4% in the fourth quarter, HoldingsChannel reports. The firm owned 6,563 shares of the medical instruments supplier’s stock after selling 602 shares during the period. Raymond James & Associates’ holdings in Atrion were worth $3,672,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of Atrion during the 3rd quarter worth $29,000. Great West Life Assurance Co. Can purchased a new stake in shares of Atrion during the 3rd quarter worth $52,000. Harbor Investment Advisory LLC lifted its stake in shares of Atrion by 26.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 114 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 24 shares during the last quarter. Royal Bank of Canada raised its stake in Atrion by 44.1% in the third quarter. Royal Bank of Canada now owns 134 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 41 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Atrion in the third quarter valued at about $106,000. 64.90% of the stock is currently owned by hedge funds and other institutional investors.

Atrion Stock Performance

Atrion stock opened at $543.05 on Friday. The stock has a 50-day moving average of $609.47 and a two-hundred day moving average of $618.47. Atrion Co. has a one year low of $534.99 and a one year high of $705.74. The stock has a market cap of $955.77 million, a PE ratio of 32.29 and a beta of 0.47.

Atrion (NASDAQ:ATRI – Get Rating) last announced its quarterly earnings data on Monday, February 27th. The medical instruments supplier reported $4.70 earnings per share for the quarter. The business had revenue of $42.86 million for the quarter. Atrion had a return on equity of 12.36% and a net margin of 17.01%.

Atrion Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 30th. Stockholders of record on Thursday, June 15th will be issued a $2.15 dividend. This represents a $8.60 dividend on an annualized basis and a dividend yield of 1.58%. The ex-dividend date of this dividend is Wednesday, June 14th. Atrion’s dividend payout ratio is presently 51.13%.

Analysts Set New Price Targets

A number of research firms have commented on ATRI. StockNews.com began coverage on Atrion in a research note on Thursday, May 18th. They issued a “hold” rating for the company. TheStreet cut Atrion from a “b-” rating to a “c” rating in a research note on Monday.

Atrion Company Profile

(Get Rating)

Atrion Corp. engages in the manufacture and development of products for medical applications. It offers products for cardiovascular, fluid delivery, and ophthalmic. It also offers contract manufacturing and kitting services, and marine & aviation inflation components. The company was founded in 1944 and is headquartered in Allen, TX.